ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Breast Latest NewsMORE >>

According to findings recently published online in the Journal of Clinical Oncology, 12 weeks of neoadjuvant T-DM1 (ado-trastuzumab emtansine; Kadcyla) with or without endocrine therapy induced superior pathologic complete response (pCR) compared with trastuzumab (Herceptin) plus endocrine therapy in patients with HER2-positive/HR-positive early breast cancer.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.